Hormonal
Tirzepatide (TZP) significantly reduces total fat mass, visceral adipose tissue, and waist circumference in individuals with overweight or obesity, with effects superior to other anti-obesity medications like dulaglutide and semaglutide.
Tirzepatide is a highly effective weekly injectable treatment for obesity that significantly reduces fat mass and visceral fat, outperforming other common medications like semaglutide. While it does cause some loss of lean mass, the disproportionate loss of fat leads to improved body composition ratios. Patients should expect weekly injections and potential gastrointestinal side effects, but the long-term benefits for body fat distribution are substantial.
TZP was shown to result in a significant reduction in total fat mass (FM), visceral adipose tissue (VAT) and waist circumference (WC) between baseline and short as well as intermediate follow-ups. Compared to other anti-obesity medications (e.g., dulaglutide and semaglutide) taken over the same duration, TZP showed a superior decrease in body fat compartments (i.e., total FM, VAT and WC).
Why this rating
Based on 6 high-quality RCTs with low risk of bias, though narrative synthesis limits meta-analysis.
Source
De las ideas a los proyectos : la creatividad como pilar básico del emprendimiento
Mariona Masgrau Juanola et al. · Aula de innovación educativa · 2012
DOI 10.3390/diseases12090204
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →